At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Preemptive Pharmacogenomic Testingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Use of Preemptive Pharmacogenomic Testing to Personalize Supportive Oncology
In Brief
A clinical study evaluating Preemptive Pharmacogenomic Testing for Cancer and 2 related conditions. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer. The investigators aim to understand how PGx testing can be used to improve medication management for pain and depression, and whether PGx-guided prescribing improves these symptoms and quality of life compared to historical controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Depression, Pain
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartDec 2020
Primary CompletionDec 2023
TodayJul 2026
First PostedAug 5, 2020
Enrollment StartDec 2, 2020
Primary CompletionDec 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.9 years ago
Interventions
Preemptive Pharmacogenomic Testingother
The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.